The fourth TP53mut AML sample, SCXC-7575, had co-mutations in IDH2, ASXL1, KRAS and CEBPA (Supplementary Table 1E) with recent studies correlating IDH2 or ASXL1 co-mutations with improved responses to therapy in TP53mut AML1. This evidence concerns the gene KRAS and acute myeloid leukemia.